微创心通医疗科技有限公司是一家领先的医疗器械企业，专注于心脏瓣膜疾病领域的创新性和潜在最优整体解决方案的研发和商业化。本集团自主研发的第一代经导管主动脉瓣植入（“TAVI”） 产品VitaFlow®已于2019年7月获国家药监局审批并随后于2019年8月在中国进行商业化。
Investors 2
Mentions in press and media 1
| Date | Title | Description |
| 31.03.2022 | 4C Medical Technologies Nabs $35M, Appoints New President and CEO | What You Should Know:
– 4C Medical Technologies, a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease raises $35.4M in Series C funding was led by MicroPort Card... |
Reviews 0
